Elena Goicoechea de Jorge

Elena Goicoechea de Jorge

Auto-generated profile, based on publicly available information

Elena Goicoechea de Jorge

Department of Molecular and Cellular Biosciences, Center for Biological Research Margarita Salas and Research Institute Hospital 12 de Octubre (imas12), Madrid, Spain

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2013 in Kidney International
Verified
Journal Article
Open access
MPMatthew C. Pickering
Matthew C. Pickering
VDVivette D. D'Agati
Vivette D. D'Agati
CNCarla M. Nester
Carla M. Nester
RSRichard J. H. Smith
Richard J. H. Smith
MHMark Haas
Mark Haas
HCH. Terence Cook
H. Terence Cook
C3 glomerulopathy is a recently introduced pathological entity whose original definition was glomerular pathology characterized by C3 accumulation with absent or scanty immunoglobulin deposition. In August 2012, an invited group of experts (comprising the authors of this document) in renal pathology, nephrology, complement biology, and complement therapeutics met to discuss C3 glomerulopathy in the first C3 Glomerulopathy Meeting. The objectives were to reach a consensus on: the definition of C3 glomerulopathy, appropriate complement investigations that should be performed in these patients, and how complement therapeutics should be explored in the condition. This meeting report represents the current consensus view of the group.

2 January 2007 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
EJElena Goicoechea de Jorge
Elena Goicoechea de Jorge
CHClaire L. Harris
Claire L. Harris
JEJorge Esparza-Gordillo
Jorge Esparza-Gordillo
LCLuis Carreras
Luis Carreras
EAElena Aller Arranz
Elena Aller Arranz
SCSantiago Rodríguez De Córdoba
Santiago Rodríguez De Córdoba
Hemolytic uremic syndrome (HUS) is an important cause of acute renal failure in children. Mutations in one or more genes encoding complement-regulatory proteins have been reported in approximately one-third of nondiarrheal, atypical HUS (aHUS) patients, suggesting a defect in the protection of cell surfaces against complement activation in susceptible individuals. Here, we identified a subgroup of aHUS patients showing persistent activation of the complement alternative pathway and found within this subgroup two families with mutations in the gene encoding factor B (BF), a zymogen that carries the catalytic site of the complement alternative pathway convertase (C3bBb). Functional analyses demonstrated that F286L and K323E aHUS-associatedBFmutations are gain-of-function mutations that result in enhanced formation of the C3bBb convertase or increased resistance to inactivation by complement regulators. These data expand our understanding of the genetic factors conferring predisposition to aHUS, demonstrate the critical role of the alternative complement pathway in the pathogenesis of aHUS, and provide support for the use of complement-inhibition therapies to prevent or reduce tissue damage caused by dysregulated complement activation.

1 September 2010 in The Lancet
Verified
Journal Article
Open access
DGDaniel P Gale
Daniel P Gale
EJElena Goicoechea de Jorge
Elena Goicoechea de Jorge
HCH Terence Cook
H Terence Cook
RMRubén Martinez-Barricarte
Rubén Martinez-Barricarte
AHAndreas Hadjisavvas
Andreas Hadjisavvas
MPMatthew C Pickering
Matthew C Pickering
Complement is a key component of the innate immune system, and variation in genes that regulate its activation is associated with renal and other disease. We aimed to establish the genetic basis for a familial disorder of complement regulation associated with persistent microscopic haematuria, recurrent macroscopic haematuria, glomerulonephritis, and progressive renal failure. We sought patients from the West London Renal and Transplant Centre (London, UK) with unusual renal disease and affected family members as a method of identification of new genetic causes of kidney disease. Two families of Cypriot origin were identified in which renal disease was consistent with autosomal dominant transmission and renal biopsy of at least one individual showed C3 glomerulonephritis. A mutation was identified via a genome-wide linkage study and candidate gene analysis. A PCR-based diagnostic test was then developed and used to screen for the mutation in population-based samples and in individuals and families with renal disease. Occurrence of familial renal disease cosegregated with the same mutation in the complement factor H-related protein 5 gene (CFHR5). In a cohort of 84 Cypriots with unexplained renal disease, four had mutation in CFHR5. Overall, we identified 26 individuals with the mutation and evidence of renal disease from 11 ostensibly unrelated kindreds, including the original two families. A mutant CFHR5 protein present in patient serum had reduced affinity for surface-bound complement. We term this renal disease CFHR5 nephropathy. CFHR5 nephropathy accounts for a substantial burden of renal disease in patients of Cypriot origin and can be diagnosed with a specific molecular test. The high risk of progressive renal disease in carriers of the CFHR5 mutation implies that isolated microscopic haematuria or recurrent macroscopic haematuria should not be regarded as a benign finding in individuals of Cypriot descent. UK Medical Research Council and Wellcome Trust.

4 March 2013 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
EJElena Goicoechea de Jorge
Elena Goicoechea de Jorge
JCJoseph J. E. Caesar
Joseph J. E. Caesar
TMTalat H. Malik
Talat H. Malik
MPMitali Patel
Mitali Patel
MCMatthew Colledge
Matthew Colledge
SLSusan M. Lea
Susan M. Lea
The complement system is a key component regulation influences susceptibility to age-related macular degeneration, meningitis, and kidney disease. Variation includes genomic rearrangements within the complement factor H-related ( CFHR ) locus. Elucidating the mechanism underlying these associations has been hindered by the lack of understanding of the biological role of CFHR proteins. Here we present unique structural data demonstrating that three of the CFHR proteins contain a shared dimerization motif and that this hitherto unrecognized structural property enables formation of both homodimers and heterodimers. Dimerization confers avidity for tissue-bound complement fragments and enables these proteins to efficiently compete with the physiological complement inhibitor, complement factor H (CFH), for ligand binding. Our data demonstrate that these CFHR proteins function as competitive antagonists of CFH to modulate complement activation in vivo and explain why variation in the CFHRs predisposes to disease.

20 January 2005 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
JEJorge Esparza-Gordillo
Jorge Esparza-Gordillo
EJElena Goicoechea de Jorge
Elena Goicoechea de Jorge
ABAlfonso Buil
Alfonso Buil
LBLuis Carreras Berges
Luis Carreras Berges
Margarita López-TrascasaMargarita López-Trascasa
Margarita López-Trascasa
SCSantiago Rodríguez De Córdoba
Santiago Rodríguez De Córdoba
The efficiency of the complement system as an innate immune defense mechanism depends on a fine control that restricts its action to pathogens and prevents non-specific damage to host tissues. Genetic and functional analyses have shown that this critical control of complement activation may be impaired in atypical hemolytic uremic syndrome (aHUS) patients. Mutations in HF1 , MCP or FI have been found in aHUS patients, but incomplete penetrance of the disease in individuals carrying these mutations is relatively frequent and no genetic defect has yet been found in a majority of aHUS patients. We report here the identification of a specific SNP haplotype block, spanning the MCP gene in the regulators of complement activation gene cluster, which is over-represented in aHUS patients and strongly associates with the severity of the disease. Linkage disequilibrium analyses suggest that this SNP haplotype also includes the CR1 , DAF and C4BP genes. Initial studies identified two SNPs in the haplotype that influence the transcription activity of the MCP promoter in transient transfection experiments. Notably, the SNP haplotype block was found to be particularly frequent among patients who carry mutations in HF1 , MCP or FI . These findings and the identification of aHUS patients carrying mutations in two complement regulatory genes provide an important insight into the etiology of aHUS. Together, they suggest that complement regulatory molecules act as a protein network and that multiple hits, involving plasma- and membrane-associated complement regulatory proteins, are necessary to impair protection to host tissues and to confer significant predisposition to aHUS.

7 December 2007 in Clinical and Experimental Immunology
Verified
Journal Article
Closed access
PDF file
SCSantiago Rodríguez De Córdoba
Santiago Rodríguez De Córdoba
EJE. Goicoechea De Jorge
E. Goicoechea De Jorge